8/2/2019 Perfil de TBC Para Colombia

1/1

Colombia

Tuberculosis profile

Population 2010 (millions) 46

Estimates of burden * 2010 Number (thousands)Rate

(per 100 000 pop)

Mortality (excluding HIV) 1.3 (0.81.9) 2.8 (1.74.2)

Prevalence (incl HIV) 22 (9.137) 48 (2081)

Incidence (incl HIV) 16 (13

19) 34 (28

41)

Incidence (HIV-positive) 1.1 (0.751.5) 2.4 (1.63.3)

Case detection, all forms (%) 72 (6087)

Case notifications 2010

New cases (%) Retreatment cases (%)

Smear-positive 7 028 (64) Relapse 400 (46)

Smear-negative 1 319 (12) Treatment after failure 61 (7)

Smear unknown 377 (3) Treatment after default 408 (47)

Extrapulmonary 1 985 (18) Other 0 (0)

Other 311 (3)

Total new 11 020 Total retreatment 869

Total < 15 years 719

Total new and relapse 11 420 (96% of total)

Total cases notified 11 889

Drug regimens

Rifampicin used throughout treatment Yes

% of patients treated with fixed-dose combinations (FDCs) 100

Paediatric formulations procured Yes

Incidence (HIV+TB in orange), notifications (black)

(rates per 100 000 population)

1990 1992 1994 1996 1998 2000 2002 2004 2006 20082010

0

20

40

60

80

Prevalence (rate per 100 000 population)

19901992199419961998200020022004200620082010

0

50

100

150

200

Mortality excluding HIV(rate per 100 000 population)

1990 1992 1994 1996 1998 2000 2002 2004 2006 20082010

02

4

6

810

Treatment success rate 2009 (%)

New smear-positive 77

New smear-negative/extrapulmonary 71

Retreatment

Treatment success rate (%)

199519961997199819992000200120022003200420052006200720082009

0

40

80 New smear +

New smear-/extrap

Retreatment

TB/HIV 2010

TB patients with known HIV status 5 079

% of TB patients with known HIV status 43

TB patients that are HIV-positive 1 231

% of tested TB patients that are HIV-positive 24% HIV-positive TB patients started on CPT

% HIV-positive TB patients started on ART 35

HIV-positive people screened for TB

HIV-positive people provided with IPT

CPT (orange) and ART (green) for HIV-positive TB patients (blue)

2003 2004 2005 2006 2007 2008 2009 2010

0

500

1000

1500

MDR-TB, Estimates among notified cases *

% of new TB cases with MDR-TB 1.5 (0.802.4)

% of retreatment TB cases with MDR-TB 16 (1319)

Estimated MDR-TB cases among new

pulmonary TB cases notified in 2010140 (72220)

Estimated MDR-TB cases among retreatedpulmonary TB cases notified in 2010 140 (110170)

MDR-TB reported cases 2010 NewRetreat-

ment Total

Cases tested for MDR-TB 1 240 495 2 001

% of notified tested for MDR-TB 11 57 17

Confirmed cases of MDR-TB 48 78 131

MDR-TB patients started treatment 152

Financing 2011 2012

Total budget (US$ millions) 8 9

Available funding (US$ millions) 6 8

% of budget funded 76 82

% available funding from domestic sources 100 87

% available funding from Global Fund 0 13

NTP Budget (blue) and available funding (green) (US$ millions)

2006 2007 2008 2009 2010 2011 2012

24

6

8

1012

Laboratories 2009 2010 2011

Smear (per 100 000 population) 5.3 7.9 7.8

Culture (per 5 million population) 140.8 135.7 133.8

DST (per 10 million population) 0.4 0.8 0.9

Second-line DST available In and outside country

National Reference Laboratory Yes

* Ranges represent uncertainty intervals Generated: March 10, 2012 Source: www.who.int/tb/data

http://www.who.int/tb/data/